Search results

Skip to results

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 31 to 36 of 36 results for certolizumab pegol

  1. Certolizumab pegol for the treatment of rheumatoid arthritis (TA186)

    This guidance has been updated and replaced by NICE technology appraisal guidance 375.

    Technology appraisal guidance
    Published
    24 February 2010

  2. Psoriasis: assessment and management (CG153)

    This guideline covers assessing and managing psoriasis in adults, young people and children. It aims to improve long-term disease control and quality of life for people with psoriasis.

    Clinical guideline
    Last updated
    1 September 2017
    View recommendations

    Sections for CG153

  3. Guselkumab for treating active psoriatic arthritis after inadequate response to DMARDs (TA815)

    Evidence-based recommendations on guselkumab (Tremfya) for active psoriatic arthritis after inadequate response to DMARDs in adults.

    Technology appraisal guidance
    Published
    10 August 2022
    View recommendations

    Sections for TA815

  4. Apremilast for treating active psoriatic arthritis (TA433)

    Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis.

    Technology appraisal guidance
    Published
    22 February 2017
    View recommendations

    Sections for TA433

  5. RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease (MIB109)

    NICE has developed a medtech innovation briefing (MIB) on RIDASCREEN tests for monitoring infliximab in inflammatory bowel disease .

    Medtech innovation briefing
    Published
    20 June 2017

  6. Ustekinumab for treating active psoriatic arthritis (TA340)

    Evidence-based recommendations on ustekinumab (Stelara) for treating active psoriatic arthritis in adults.

    Technology appraisal guidance
    Last updated
    3 March 2017
    View recommendations

    Sections for TA340